The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey

SERİN, ELİF NAZLI; ATAS, Unal; ÇETINKAYA, RAMAZAN; SARI, FUNDA

doi:10.53394/akd.1136791

The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey

Elif Nazlı SERiN, (Akdeniz Üniversitesi, Tıp Fakültesi, İç Hastalıkları Bölümü, Endokrinoloji Bilim Dalı, Antalya, Türkiye)

Ünal ATAŞ, (Aksaray Eğitim ve Araştırma Hastanesi, Hematoloji Bölümü, Aksaray, Türkiye)

Ramazan ÇETİNKAYA, (Akdeniz Üniversitesi, Tıp Fakültesi, İç Hastalıkları Bölümü, Nefroloji Bilim Dalı, Antalya, Türkiye)

Funda SARI (Akdeniz Üniversitesi, Tıp Fakültesi, İç Hastalıkları Bölümü, Nefroloji Bilim Dalı, Antalya, Türkiye)

Akdeniz Tıp Dergisi

0 0

Yıl: 2024 Cilt: 10 Sayı: 1 Sayfa Aralığı: 92 - 99 Metin Dili: İngilizce DOI: 10.53394/akd.1136791 İndeks Tarihi: 27-03-2024

The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey

Öz:

Objective: The aim of the present study was to identify patients with chronic kidney disease of unknown etiology or of other detected etiology among those who were undergoing hemodialysis in the Western Mediterranean region and to detect the prevalence of Fabry mutation in these patients. In addition, we aimed to screen the family members of the cases with mutations in our study. Methods: A total of 664 patients over the age of 18 who received hemodialysis treatment in 11 different hemodialysis centers in the Western Mediterranean region of Turkey were screened. Alpha-galactosidase A enzyme levels were first tested in male patients, and for patients with alpha-galactosidase A levels < 3.3 nmol/mL/h, GLA gene sequence analysis was performed. GLA gene sequence analysis was performed directly in female patients. Results: In total 664 patients [313 (47.1%) male and 351 (52.9%) female] have been scanned. Fabry mutation was positive in eight female patients and one male patient. Conclusion: According to the output of the research, the prevalence of Fabry disease among the patients who received hemodialysis treatment was determined as 1.35%. In order to eliminate the conflicts upon whether the mutations which is effective on the etiology of Fabry disease are pseudo alleles it is required that new researches should be done, prospective scanning programs in a wider patient population and genetic consultancy and preventive medicine services should become more prevalent.

Anahtar Kelime: Fabry disease Chronic kidney disease Hemodialysis

Türkiye'nin Batı Akdeniz Bölgesindeki Hemodiyaliz Hastalarında Fabry Hastalığı Sıklığı

Öz:

Amaç: Bu çalışmanın amacı, Batı Akdeniz bölgesinde hemodiyaliz uygulanan ancak böbrek yetmezliği etiyolojisi bilinmeyen veya başka nedenlere bağlanan hastaları belirlemek ve bu hastalardaki Fabry mutasyonunun prevalansını saptamaktır. Ayrıca, çalışmamızda mutasyon saptanan olguların aile bireylerinde de tarama yapmayı amaçladık. Yöntemler: Türkiye'de Batı Akdeniz bölgesinde 11 farklı hemodiyaliz merkezinde hemodiyaliz tedavisi gören 18 yaş üstü 664 hasta tarandı. Erkek hastalarda ilk olarak Alfa-galaktosidaz A enzim seviyeleri test edildi ve alfa-galaktosidaz A seviyeleri < 3,3 nmol/mL/saat olan hastalarda GLA gen dizi analizi yapıldı. Kadınlarda ise GLA gen dizi analizi doğrudan yapıldı. Bulgular: Toplam 664 hasta [313 (%47,1) erkek ve 351 (%52,9) kadın] tarandı. Fabry mutasyonu sekiz kadın hastada ve bir erkek hastada pozitifti. Sonuç: Araştırmamızda hemodiyaliz tedavisi alan hastalarda Fabry hastalığı prevalansı %1,35 olarak belirlendi. Fabry hastalığının etiyolojisinde etkili olan mutasyonların yalancı alel olup olmadığı konusundaki çelişkileri ortadan kaldırmak için yeni araştırmaların yapılması, daha geniş hasta popülasyonunda prospektif tarama programlarının yapılması, genetik danışmanlık ve koruyucu hekimlik hizmetlerinin yaygınlaştırılması gerekmektedir.

Anahtar Kelime: Fabry hastalığı Kronik böbrek hastalığı Hemodiyaliz

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1.El-Abassi R, Singhal D, England JD. Fabry's disease. J Neurol Sci. 2014;344(1-2):5-19.
2. Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903-7.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-54.
4. Masson C, Cisse I, Simon V, Insalaco P, Audran M. Fabry disease. Joint Bone Spine. 2004;71(5):381-3.
5. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19-27.
6. Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015;162(11):1-16.
7. Desnick RJ, Ioannou YA, Eng CM. a-Galactosidase A deficiency: Fabry disease. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995:2741-84.
8. Kuhn H, Kohler E, Hort W, Frenzel H. Concealed myocardial storage disease (Fabry’s disease): pitfalls in the diagnosis of hypertrophic nonobstructive cardiomyopathy. Circulation 1982;66(Suppl. II):117.
9. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801-7.
10. Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, Roscher AA, Muntau AC. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl. 2006;95(451):30-8.
11. Moiseev S, Fomin V, Savostyanov K, Pushkov A, Moiseev A, Svistunov A, Namazova-Baranova L. The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron. 2019;141(4):249-55.
12. Suleymanlar G. Hemodialysis. In; Suleymanlar G, Ates K, Seyahi N editors. Registry Of The Nephrology, Dialysis And Transplantation In Turkey. Ankara: Miki Press; 2019; p10.
13. Gundogdu A, Kotan D, Alemdar M. The Frequency of Fabry Disease among Young Cryptogenic Stroke Patients in the City of Sakarya. J Stroke Cerebrovasc Dis. 2017;26(6):1334-40.
14. Barman HA, Özcan S, Atıcı A, Özgökçe C, Öztürk A, Kafalı AE, Çakar NE, Tavşanlı ME, Küçük M, Şahin I, Okuyan E. Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey. Anatol J Cardiol. 2020;23(2):79-85.
15. Boscaro F, Pieraccini G, Marca Gl, Bartolucci G, Luceri C, Luceri F, Moneti G. Rapid quantitation of globotriaosylceramide in human plasma and urine:a potential application for monitoring enzyme replacement therapy in Andreson-Fabry disease. Rapid Commun Mass Spectrom. 2002;16(16):1507-14.
16. Winchester B, Young E. Biochemical and genetic diagnosis of Fabry disease. In. Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford Pharma Genesis 2006.
17. Stark S, Fong B, Fletcher J, Fietz M. Screening For Fabry Disease Using Dried Blood Spots. In: Abstracts for the 38th Human Genetics Society of Australasia Annual Scientific Meeting Adelaide, South Australia; August 3-6, 2014; Twin Research and Human Genetics; 2014. p. 322-46.
18. Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E, Wanner C, Zhang K, Warnock DG. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant. 2009;24(6):1736-43.
19. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract. 2007;61(2):293-302.
20. Veen SJ, Hollak CEM, Kuilenburg ABP, Langeveld M. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020;43(5):908-921.
21. Bülbül SF, Dursun O, Dursun ZE. Physicians, Who are Working in Kırıkkale, Awareness of Fabry Disease and Inherited Metabolic Diseases. J LSD 2012;4(1):1-8.
22. Okur I, Ezgu F, Biberoglu G, Tumer L, Erten Y, Isitman M, Eminoglu FT, Hasanoglu A. Screening for Fabry Disease in Patients Undergoing Dialysis for Chronic Renal Failure in Turkey: Identification of New Case With Novel Mutation. Gene. 2013;527(1):42-7.
23. Sayilar EI, Ayar Y, Yavuz M. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province. Clin Nephrol. 2016;85(3):165-72.
24. Yalın SF, Eren N, Sinangil A, Yilmaz VT, Tatar E, Ucar AR, Sevinc M, Can Ö, Gurkan A, Arik N, Alisir Ecder S, Uyar M, Yasar M, Gulcicek S, Mese M, Dheir H, Cakir U, Köksal Cevher Ş, Turkmen K, Guven B, Guven Taymez D, Erkalma Senates B, Ecder T, Kocak H, Uslu A, Demir E, Basturk T, Ogutmen MB, Kinalp C, Dursun B, Bicik Bahcebasi Z, Sipahi S, Dede F, Oruc M, Caliskan Y, Genc A, Yelken B, Altıparmak MR, Turkmen A, Seyahi N. Fabry Disease Prevalence in Renal Replacement Therapy in Turkey. Nephron. 2019;142(1):26-33.
25. Turkmen K, Guçlu A, Sahin G, Kocyigit I, Demirtas L, Erdur FM, Sengül E, Ozkan O, Emre H, Turgut F, Unal H, Karaman M, Acıkel C, Esen H, Balli E, Bıtırgen G, Tonbul HZ, Yılmaz MI, Ortiz A. The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study. Kidney Blood Press Res. 2016;41(6):1016-24.
26. Saito O, Kusano E, Akimoto T, Asano Y, Kitagawa T, Suzuki K, Ishige N, Akiba T, Saito A, Ishimura E, Hattori M, Hishida A, Guili C, Maruyama H, Kobayashi M, Ohashi T, Matsuda I, Eto Y. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol. 2016;20(2):284-93.
27. Capuano I, Garofalo C, Buonanno P, Pinelli M, Risi TD, Feriozzi S, Riccio E, Pisani A. Identifying Fabry Patients in Dialysis Population: Prevalence of GLA Mutations by Renal Clinic Screening, 1995-2019. J Nephrol. 2020;33(3):569-81.
28. Silva CAB, Barreto FC, Reis MAD, Junior JAM, Cruz CMS. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening. Nephron. 2016;134(4):221-30.
29. Arslan K, Eröz R, Özmerdivenli R. Bati karadeniz bölgesinin Eskipazar ilçesinde akraba evliliği durumu, bununla ilişkili kronik ve genetik hastalik sikliğinin araştirilmasi. Duzce Medical Journal. 2016; 18(2):54-9.
30. Hamamy H, Alwan A. Hereditary disorders in the Eastern Mediterranean Region. Bull World Health Organ. 1994; 72(1):145-54.
31. Kantarci S, Eraslan S, Laleli K. Türk Toplumunda Sık Görülen Kalıtsal Hastalıklarda PCR Tekniğine Dayalı DNA Tanı Yöntemlerinin Geliştirilmesi ve Servis Olarak Sunulması. Perinatoloji Dergisi. 1999; 7(1):15-22.
32. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alphagalactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003;80(3):307-14.
33. Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, Wanner C, Weidemann F. Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry disease. JIMD Rep. 2013;7:99-102.
34. Hasholt L, Ballegaard M, Bundgaard H, Christiansen M, Law I, Lund AM, Norremolle A, Krogh Rasmussen A, Ravn K, Tumer Z, Wibrand F, Feldt-Rasmussen U. The D313Y Variant in the GLA Gene - No Evidence of a Pathogenic Role in Fabry Disease. Scand J Clin Lab Invest. 2017;77(8):617-21.
35. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-27.
36. Colon C, Ortolano S, Alvarez JV, Lopez-Suarez OE, Couce ML, Fernández-Lorenzo JR. Newborn screening for Fabry disease in the north-west of Spain. Eur J Pediatr. 2017;176(8):1075-81.
37. Moulin Md, Koehn AF, Golsari A, Dulz S, Atiskova Y, Patten M, Münch J, Avanesov M, Ullrich K, Muschol N. The mutation p.D313Y is associated with organ manifestation in Fabry disease. Clin Genet. 2017;92(5):528-33.
38. Tol Lvd, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014 Jan;51(1):1-9.
39. Yeniçerioğlu Y, Akdam H, Dursun B, Alp A, Eyiler FS, Akın D, Gün Y, Hüddam B, Batmazoğlu M, Gibyeli Genek D, Pirinççi S, Ersoy İR, Üzüm A, Soypaçacı Z, Tanrısev M, Çolak H, Demiral Sezer S, Bozkurt G, Akyıldız UO, Akyüz Ünsal Aİ, Ünübol M, Uslu M, Eryılmaz U, Günel C, Meteoğlu İ, Yavaşoğlu İ, Ünsal A, Akar H, Okyay P. Screening Fabry's Disease in Chronic Kidney Disease Patients Not on Dialysis: A Multicenter Study. Ren Fail. 2017;39(1):104-11.
40. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353(1-2):201-3.
41. Lin CJ, Chien YH, Lai TS, Shih HM, Chen YC, Pan CF, Chen HH, Hwu WL, Wu CJ. Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients With Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center. Kidney Blood Press Res. 2018;43(5):1636-45.
42. Uçar S.K, Sozmen E, Duman S, Başçi A, Çoker M. Alpha-galactosidase A Activity Levels in Turkish Male Hemodialysis Patients. Ther Apher Dial. 2012;16(6):560-65.
43. Shabbeer J, Yasuda M, Luca E, Desnick RJ. Fabry disease: 45 novel mutations in the a-galactosidase A gene causing the classical phenotype. Mol Genet Metab. 2002;76(1):23-30.

APA	SERİN E, ATAS U, ÇETINKAYA R, SARI F (2024). The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. , 92 - 99. 10.53394/akd.1136791
Chicago	SERİN ELİF NAZLI,ATAS Unal,ÇETINKAYA RAMAZAN,SARI FUNDA The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. (2024): 92 - 99. 10.53394/akd.1136791
MLA	SERİN ELİF NAZLI,ATAS Unal,ÇETINKAYA RAMAZAN,SARI FUNDA The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. , 2024, ss.92 - 99. 10.53394/akd.1136791
AMA	SERİN E,ATAS U,ÇETINKAYA R,SARI F The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. . 2024; 92 - 99. 10.53394/akd.1136791
Vancouver	SERİN E,ATAS U,ÇETINKAYA R,SARI F The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. . 2024; 92 - 99. 10.53394/akd.1136791
IEEE	SERİN E,ATAS U,ÇETINKAYA R,SARI F "The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey." , ss.92 - 99, 2024. 10.53394/akd.1136791
ISNAD	SERİN, ELİF NAZLI vd. "The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey". (2024), 92-99. https://doi.org/10.53394/akd.1136791

APA	SERİN E, ATAS U, ÇETINKAYA R, SARI F (2024). The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. Akdeniz Tıp Dergisi, 10(1), 92 - 99. 10.53394/akd.1136791
Chicago	SERİN ELİF NAZLI,ATAS Unal,ÇETINKAYA RAMAZAN,SARI FUNDA The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. Akdeniz Tıp Dergisi 10, no.1 (2024): 92 - 99. 10.53394/akd.1136791
MLA	SERİN ELİF NAZLI,ATAS Unal,ÇETINKAYA RAMAZAN,SARI FUNDA The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. Akdeniz Tıp Dergisi, vol.10, no.1, 2024, ss.92 - 99. 10.53394/akd.1136791
AMA	SERİN E,ATAS U,ÇETINKAYA R,SARI F The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. Akdeniz Tıp Dergisi. 2024; 10(1): 92 - 99. 10.53394/akd.1136791
Vancouver	SERİN E,ATAS U,ÇETINKAYA R,SARI F The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey. Akdeniz Tıp Dergisi. 2024; 10(1): 92 - 99. 10.53394/akd.1136791
IEEE	SERİN E,ATAS U,ÇETINKAYA R,SARI F "The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey." Akdeniz Tıp Dergisi, 10, ss.92 - 99, 2024. 10.53394/akd.1136791
ISNAD	SERİN, ELİF NAZLI vd. "The Frequency of Fabry Disease in Hemodialysis Patients in the Western Mediterranean Region of Turkey". Akdeniz Tıp Dergisi 10/1 (2024), 92-99. https://doi.org/10.53394/akd.1136791